Terconazole: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Vaginal
Vulvovaginal candidiasis

Adult: As 0.4% vaginal cream: Insert 1 applicatorful (5 g) once daily at bedtime for 7 days. As 0.8% vaginal cream: Insert 1 applicatorful (5 g) once daily at bedtime for 3 days. As vaginal supp: Insert 1 supp (80 mg) once daily at bedtime for 3 days.

Contraindications

Hypersensitivity.

Special Precautions

Pregnancy and lactation.

Adverse Reactions

Significant: Hypersensitivity reactions, including anaphylaxis; idiosyncratic reactions (e.g. fever, chills, or other flu-like symptoms); dermatologic reactions (e.g. local irritation/sensitisation, toxic epidermal necrolysis).
Gastrointestinal disorders: Abdominal pain.
General disorders and administration site conditions: Body pain.
Nervous system disorders: Headache.
Reproductive system and breast disorders: Dysmenorrhoea; vaginal burning sensation, itching or pain.

Pregnancy Category (US FDA)

Topical/Vag: C

Patient Counseling Information

Discontinue use and avoid retreatment if irritation, sensitisation, chills, fever, or other flu-like symptoms occur. May decrease the effectiveness of latex contraceptives (e.g. condoms, diaphragms); use alternative contraceptive measures.

Monitoring Parameters

For patients who lack response to terconazole, a repeat K hydroxide smear and/or culture should be performed to confirm the diagnosis and rule out other pathogens.

Action

Description:
Mechanism of Action: Terconazole is a triazole derivative antifungal agent that inhibits the cytochrome P450-mediated 14-α-demethylase of susceptible fungi. This activity leads to the accumulation of membrane-disrupting 14-α-demethylsterols and loss of ergosterol in the fungal cell wall.
Pharmacokinetics:
Absorption: Absorbed systemically (5-16%). Time to peak plasma concentration: Approx 5-10 hours.
Distribution: Plasma protein binding: 94.9%.
Metabolism: Extensively metabolised in the liver.
Excretion: Vaginal supp: Via urine (3-10%); faeces (2-6%). Elimination half-life: 6.4-8.5 hours.

Chemical Structure

Storage

Store between 15-30°C.

MIMS Class

Preparations for Vaginal Conditions

ATC Classification

G01AG02 - terconazole ; Belongs to the class of triazole derivative antiinfectives. Used in the treatment of gynecological infections.

References

Brayfield A, Cadart C (eds). Terconazole. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/03/2025.

Terconazole Cream (Taro Pharmaceuticals U.S.A., Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/03/2025.

Terconazole Suppository (Padagis Israel Pharmaceuticals Ltd). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/03/2025.

Terconazole Vaginal Cream 0.8% (E. Fougera & Co. a Division of Fougera Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/03/2025.

Terconazole Vaginal Cream 0.8% (E. Fougera and Company). U.S. FDA. https://www.fda.gov. Accessed 03/03/2025.

Terconazole. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/03/2025.

Terconazole. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/03/2025.

Disclaimer: This information is independently developed by MIMS based on Terconazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com